Also found in: Medical.
VEGFR1Vascular Endothelial Growth Factor Receptor 1
References in periodicals archive ?
Cao, "Positive and negative modulation of angiogenesis by VEGFR1 ligands," Science Signaling, vol.
For example, Sirna is investigating the regulation of angiogenesis in AMD by targeting multiple VEGF receptors -- VEGFR1 and VEGFR2 -- using a single siRNA molecule.
To identify potential subgroups of rectal cancer patients who might benefit from cetuximab-based neoadjuvant radiochemotherapy, we assessed gene expression of factors involved in tumor growth (EGFR), angiogenesis (VEGF, VEGFR1, VEGFR2d), DNA repair (ERCC1) and drug metabolism (TS), as well as KRAS gene mutation status.
sup][21] Conbercept is a recombinant fusion protein containing the second Ig domain of VEGFR1, the third and fourth Ig domains of VEGFR2, and the Fc region of human IgG.
This phenomenon has prompted the development of therapeutic approaches targeting molecules involved in the formation of pathological blood vessels such as VEGF and its receptors VEGFR1, VEGFR2 and VEGFR3.
131) Pazopanib is also a TKI targeting VEGFR1, -2, and -3; PDGFR-[alpha] and -[beta] FGFR-1 and -3; and c-kit.
tres receptores denominados VEGFR1 (flt1), VEGFR2 (KDR/FLk1) y VEGFR3 (FLt4).
Furthermore, TAMs express VEGFR1 (flt1) [18] and respond to its activation by migrating and modulating their biological activity in response to VEGFR1 ligands [19] such as VEGF produced by tumour cells.
These data provide the foundation for developing a new diagnostic test for improving a) chemotherapy response for bladder cancer patients; and b) defining new gene combinations that may help predict clinical benefit from chemotherapy of colorectal cancer, specifically the association between KRAS status, gene expression levels of VEGFR-2, ERCC1 and EGFR with clinical outcome to chemotherapy combination 5-FU, oxaliplatin and bevacizumab (FOLFOX/BV) therapy in patients with metastatic colorectal cancer; and c) showing that VEGF and VEGFR1 gene expression levels may predict tumor recurrence risk in colon cancer patients and help identify patients likely to benefit from adjuvant chemotherapy.
58) In addition to KIT and PDGFR, it targets VEGFR1 and VEGFR2, FLT3, and RET.
Abstract No: 4040: VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer.